Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [22]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-11976 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB2 (HER-2) Antibody Cocktail
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-11976 targets HER-2 in WB applications and shows reactivity with Human samples.
- Antibody clone number
- L87, 2ERB19
- Concentration
- 0.2 mg/mL
Submitted references Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway.
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.
Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells.
Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer.
Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.
Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin.
Sequestering ErbB2 in endoplasmic reticulum by its autoinhibitor from translocation to cell surface: an autoinhibition mechanism of ErbB2 expression.
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu.
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick-Silverman L, DiFeo A, Johnston D, Reynolds SR, Roses DF, Mosoian A
PloS one 2013;8(1):e55145
PloS one 2013;8(1):e55145
Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway.
Kuo HP, Hsu SC, Ou CC, Li JW, Tseng HH, Chuang TC, Liu JY, Chen SJ, Su MH, Cheng YC, Chou WY, Kao MC
Evidence-based complementary and alternative medicine : eCAM 2013;2013:219472
Evidence-based complementary and alternative medicine : eCAM 2013;2013:219472
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.
Sims AH, Zweemer AJ, Nagumo Y, Faratian D, Muir M, Dodds M, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP
British journal of cancer 2012 May 22;106(11):1779-89
British journal of cancer 2012 May 22;106(11):1779-89
Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM
Journal of cellular physiology 2010 Oct;225(1):256-65
Journal of cellular physiology 2010 Oct;225(1):256-65
Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells.
Peng J, Jordan VC
International journal of oncology 2010 Feb;36(2):451-8
International journal of oncology 2010 Feb;36(2):451-8
Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
Barr DJ, Ostermeyer-Fay AG, Matundan RA, Brown DA
Journal of cell science 2008 Oct 1;121(Pt 19):3155-66
Journal of cell science 2008 Oct 1;121(Pt 19):3155-66
Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer.
Lin CC, Yen MC, Lin CM, Huang SS, Yang HJ, Chow NH, Lai MD
The journal of gene medicine 2008 Jun;10(6):679-89
The journal of gene medicine 2008 Jun;10(6):679-89
Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.
Tsuda N, Chang DZ, Mine T, Efferson C, García-Sastre A, Wang X, Ferrone S, Ioannides CG
Cancer research 2007 Sep 1;67(17):8378-87
Cancer research 2007 Sep 1;67(17):8378-87
Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin.
Jung Y, Xu W, Kim H, Ha N, Neckers L
Biochimica et biophysica acta 2007 Mar;1773(3):383-90
Biochimica et biophysica acta 2007 Mar;1773(3):383-90
Sequestering ErbB2 in endoplasmic reticulum by its autoinhibitor from translocation to cell surface: an autoinhibition mechanism of ErbB2 expression.
Hu P, Zhou T, Qian L, Wang J, Shi M, Yu M, Yang Y, Zhang X, Shen B, Guo N
Biochemical and biophysical research communications 2006 Mar 31;342(1):19-27
Biochemical and biophysical research communications 2006 Mar 31;342(1):19-27
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, Katiyar K, Bradley J, Abremski K, Stow M, Rupar M, Zhuo J, Li YL, Lin Q, Burns D, Xu M, Zhang C, Qian DQ, He C, Sharief V, Weng L, Agrios C, Shi E, Metcalf B, Newton R, Friedman S, Yao W, Scherle P, Hollis G, Burn TC
Cancer biology & therapy 2006 Jun;5(6):657-64
Cancer biology & therapy 2006 Jun;5(6):657-64
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.
Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J
The EMBO journal 2006 Jul 12;25(13):3234-44
The EMBO journal 2006 Jul 12;25(13):3234-44
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT, Metz MZ, Kane SE
Breast cancer research and treatment 2005 May;91(2):187-201
Breast cancer research and treatment 2005 May;91(2):187-201
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM
Cancer research 2005 Jan 15;65(2):473-82
Cancer research 2005 Jan 15;65(2):473-82
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L
Nature structural & molecular biology 2005 Feb;12(2):120-6
Nature structural & molecular biology 2005 Feb;12(2):120-6
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD
Cancer biotherapy & radiopharmaceuticals 2005 Dec;20(6):603-13
Cancer biotherapy & radiopharmaceuticals 2005 Dec;20(6):603-13
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
Lucchese A, Stevanovic S, Sinha AA, Mittelman A, Kanduc D
Peptides 2003 Feb;24(2):193-7
Peptides 2003 Feb;24(2):193-7
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
Lucchese A, Stevanovic S, Sinha AA, Mittelman A, Kanduc D
Peptides 2003 Feb;24(2):193-7
Peptides 2003 Feb;24(2):193-7
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Shimizu H, Seiki T, Asada M, Yoshimatsu K, Koyama N
Oncogene 2003 Feb 13;22(6):831-9
Oncogene 2003 Feb 13;22(6):831-9
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu.
Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L
Proceedings of the National Academy of Sciences of the United States of America 2002 Oct 1;99(20):12847-52
Proceedings of the National Academy of Sciences of the United States of America 2002 Oct 1;99(20):12847-52
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Mittelman A, Lucchese A, Sinha AA, Kanduc D
International journal of cancer 2002 Apr 10;98(5):741-7
International journal of cancer 2002 Apr 10;98(5):741-7
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Mittelman A, Lucchese A, Sinha AA, Kanduc D
International journal of cancer 2002 Apr 10;98(5):741-7
International journal of cancer 2002 Apr 10;98(5):741-7
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-11976) on SKBR3 Cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of HER-2/ErbB2 was done on 70% confluent log phase T47D cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with HER-2/ErbB2 (L87 + 2ERB19) Mouse Monoclonal Antibody (Product # MA5-11976) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300).Panel d is a merged image showing cytoplasmic and membranous localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
